Chicago, June 26, 2024 (GLOBE NEWSWIRE) -- The global autologous stem cell & non-stem cell therapies market is experiencing significant growth, with revenue expected to rise from $5.5 billion in 2024 to $22.2 billion by 2029, at a CAGR of 32.3%. Key drivers include increasing regulatory approvals for autologous CAR T cell therapies, rising R&D investments, and growing demand for personalized medicines. However, challenges such as competition from allogeneic therapies, stringent regulatory guidelines, and reimbursement complexities pose barriers. Opportunities lie in outsourcing manufacturing activities to streamline costs and navigate regulatory landscapes. North America currently leads the market, driven by substantial investments and a robust presence of major industry players like Gilead Sciences, Bristol-Myers Squibb, and Johnson & Johnson. The market's dynamics reflect a strong focus on expanding therapeutic applications, particularly in oncology, amidst evolving regulatory landscapes and technological advancements.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=837

Autologous Non-Stem Cell Therapies Lead Market Growth in 2023, Fueled by Cancer Treatments

Autologous non-stem cell therapies, including CAR T cell-based therapies and Tumor Infiltrating Lymphocyte (TIL) therapies, dominated the market in 2023. Increasing applications in cancer treatment and ongoing R&D investments support their market expansion.

Cancer Indications Propel Fastest Growth in Autologous Therapies Market

The cancer indication segment of the autologous stem cell & non-stem cell therapies market grew significantly in 2023, driven by advancements in autologous CAR T cell therapies for diseases like multiple myeloma and leukemia. Ongoing research aims to expand these therapies to treat solid tumors, further boosting market growth.

Hospitals & Clinics Lead Utilization of Autologous Therapies, Driving Market Demand

Hospitals & clinics accounted for the largest share of the autologous stem cell & non-stem cell therapies market in 2023. Their use in treating both cancer and non-cancer diseases, alongside rising global cancer cases and the demand for personalized medicines, supports market expansion.

North America Dominates Autologous Therapies Market, Fueled by R&D Investments

North America, led by the US and Canada, holds the largest regional share in the autologous stem cell & non-stem cell therapies market. Government funding, awareness of alternative medicines, and the presence of major players like Bristol-Myers Squibb and Gilead Sciences contribute to market growth.

Europe Shows Strong Growth in Autologous Therapies Market, Supported by Research Investments

Europe is the second-largest market for autologous stem cell & non-stem cell therapies, driven by academic and research institute presence, increasing investments by key players like Novartis AG, and a focus on R&D for cell-based therapies development.

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=837

Gilead Sciences, Inc. Leads Autologous Therapies Market in 2023

Gilead Sciences, Inc. (US) held a prominent position in the autologous stem cell & non-stem cell therapies market in 2023. Known for FDA-approved treatments like YESCARTA and TECARTUS, the company operates globally with manufacturing facilities across several countries, including the US, Ireland, and Canada.

Bristol-Myers Squibb Company's Impact on Autologous Therapies Market

Bristol-Myers Squibb Company (US) emerged as a major player in the autologous stem cell & non-stem cell therapies market in 2023. The company's portfolio includes biopharmaceutical products and CAR-T cell therapies like ABECMA and BREYANZI, approved for various hematological malignancies, supported by manufacturing facilities in multiple countries.

Novartis AG's Role in Driving Autologous Therapies Market Growth

Novartis AG (Switzerland) plays a significant role in the autologous stem cell & non-stem cell therapies market through its innovative medicines segment. Kymriah, a leading autologous CAR T-cell therapy for leukemia and lymphoma, underscores the company's global presence and strategic collaborations in North America, Europe, Asia Pacific, Latin America, and Africa.

For More information, Inquire Now.

Related Reports:

Stem Cell Therapy Market

Stem Cell Assays Market

Cell based Assays Market

Biologics Safety Testing Market

Nerve Repair & Regeneration Market

Get access to the latest updates on Autologous Stem Cell & Non-stem Cell Therapy Companies and Autologous Stem Cell & Non-stem Cell Therapies Market Size

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.